Dice Molecules Holdings LLC (DICE) Stock
DICE is no longer traded. Dice Molecules Holdings LLC was acquired by Eli Lilly (LLY) on August 11, 2023.
Each DICE share was exchanged for $48.00 in cash. Prices on this page are historical; the last trade was August 8, 2023 at $47.55.
See Eli Lilly (LLY) stock →Dice Molecules Holdings LLC stock price history
DICE final trading statistics
- Final close
- $47.55
- Final trading day
- Aug 8, 2023
- Market cap at delisting
- $2.27B
- Shares outstanding
- 47.76M
- Final 52-week range
- $15.08 – $47.90
- Avg. volume (final 3 mo.)
- 1,827,380
- All-time high (split-adj.)
- $47.55 · Aug 2023
- All-time low (split-adj.)
- $13.19 · Jun 2022
- Return since IPO
- +28.9%
- Beta
- —
- Book value / share
- $11.88
- Price / book
- 4.00
Dice Molecules Holdings LLC annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $0.00 | -$81.7M | -$2.14 |
| FY2021 | $1.12M | -$48.5M | -$4.25 |
| FY2020 | $863.0K | -$23.8M | -$1.45 |
| FY2019 | $5.78M | -$13.0M | -$0.59 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Dice Molecules Holdings LLC
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.
Dice Molecules Holdings LLC stock FAQ
What happened to Dice Molecules Holdings LLC stock?
Dice Molecules Holdings LLC was acquired by Eli Lilly (LLY) on August 11, 2023. Shareholders received $48.00 in cash for each share. DICE stock stopped trading on the Nasdaq, with a final close of $47.55 on August 8, 2023.
What did Dice Molecules Holdings LLC shareholders receive?
Each DICE share was converted into $48.00 in cash. The deal was valued at about $2.4 billion.
Is DICE stock still trading?
No. DICE was delisted from the Nasdaq on August 11, 2023 and no longer trades on a U.S. exchange.
What was the last price of DICE stock?
DICE closed at $47.55 on its final trading day, August 8, 2023, for a market value of about $2.27B.
What were Dice Molecules Holdings LLC's revenue and earnings in its last full fiscal year?
Dice Molecules Holdings LLC reported revenue of $0.00 and net income of -$81.7M in fiscal 2022, its last full year as a public company.
When did Dice Molecules Holdings LLC go public?
Dice Molecules Holdings LLC stock began trading on September 15, 2021.